TCN1 as an inflammatory regulator in psoriasis: Activation of the NF-κB pathway and potential therapeutic target
International Immunopharmacology · 2025-06 · 157 · 114784
DOI: 10.1016/j.intimp.2025.114784 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025-06. Verfasst von Jian Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Guangdong College of Clinical Dermatology, Anhui Medical University, Hefei, Anhui Province, People's Republic of China; Th…. Hauptthemen laut MEDLINE: Psoriasis, NF-kappa B, Keratinocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study investigates how TCN1 regulates inflammation and the cell cycle in psoriasis, focusing on the NF-κB pathway through in vitro experiments and bioinformatics analyses. METHODS: DEGs were identified by analyzing transcriptome data from four datasets comparing psoriatic lesions and normal skin (GSE34248, GSE30999, GSE14905, and GSE13355). Validation of TCN1 expression following biologic treatment was conducted using GSE201827, GSE51440, and GSE117239. GO and GSEA were performed to explore biological pathways. The expression levels of TCN1 in psoriatic lesions and healthy skin were assessed by qPCR and immunohistochemistry (IHC). In vitro, HaCaT keratinocytes were stimulated with TNF-α and IL-17 A, and TCN1 expression was modulated through siRNA-mediated knockdown and plasmid-mediated overexpression. Subsequent changes in TCN1 and key inflammatory cytokines were evaluated by qPCR and Western blotting (WB). Furthermore, immunofluorescence assays were performed to visualize the subcellular localization of TCN1 and the nuclear translocation of phosphorylated p65 (p-p65) in HaCaT cells. Cell cycle progression was assessed using BrdU-PI flow cytometry. RESULTS: TCN1 was upregulated in psoriatic lesions, and its expression levels were positively correlated with the PASI score. Following biologic treatment, TCN1 expression was reduced. TCN1 overexpression was associated with activation of the NF-κB signaling pathway, accompanied by increased synthesis of psoriasis-related inflammatory mediators, as well as an elevated proportion of cells in the S phase of the cell cycle. CONCLUSIONS: TCN1 is essential in modulating inflammation and the cell cycle in psoriasis, implying its value as both a biomarker for diagnosis and a candidate for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Guangdong College of Clinical Dermatology, Anhui Medical University, Hefei, Anhui Province, People's Republic of China; The Fifth School of Clinical Medicine, Anhui Medical University, Hefei,…
- Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China.
- Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China; Shenzhen Children's Hospital, Shenzhen, Guangdong Province, People's Republic of China.
Zitieren
APA
Huang, J., Yu, H., Yuan, X., Zhong, Y., Li, X., & Chen, Y. (2025). TCN1 as an inflammatory regulator in psoriasis: Activation of the NF-κB pathway and potential therapeutic target. International Immunopharmacology, 157, 114784. https://doi.org/10.1016/j.intimp.2025.114784
Vancouver
Huang J, Yu H, Yuan X, Zhong Y, Li X, Chen Y. TCN1 as an inflammatory regulator in psoriasis: Activation of the NF-κB pathway and potential therapeutic target. International Immunopharmacology. 2025;157:114784. doi:10.1016/j.intimp.2025.114784
BibTeX
@article{Huang2025,
author = {Huang, Jian and Yu, Huanhuan and Yuan, Xiuqing and Zhong, Yuanqiu and Li, Xinhui and Chen, Yongfeng},
title = {TCN1 as an inflammatory regulator in psoriasis: Activation of the NF-κB pathway and potential therapeutic target},
journal = {International Immunopharmacology},
year = {2025},
volume = {157},
pages = {114784},
doi = {10.1016/j.intimp.2025.114784}
}
EUVIMED